Aditxt, Inc. (via Adifem, Inc.) to Merge with Evofem Biosciences, Inc.

Aditxt, Inc. to Acquire Evofem Biosciences, Inc. to Build a Global Women’s Health Platform

December 12, 2023

Healthcare Services

Aditxt, Inc. (NASDAQ: ADTX) signed a definitive agreement to acquire Evofem Biosciences, Inc. (OTCQB: EVFM) in a transaction with an aggregate value of approximately $100 million, using a mix of Aditxt common and preferred stock plus assumption of certain senior indebtedness. The deal is intended to create a women’s health mission within Aditxt and position Evofem’s Phexxi and other products for global expansion.

Aditxt Acquires Appili Therapeutics

October 10, 2024

Healthcare Services

Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.

Aditxt Signs Share Exchange Agreement to Acquire AiPharma Global Holdings

December 28, 2021

Healthcare Services

Aditxt (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC (AiPharma Global) in a two-step transaction involving an initial closing and a secondary closing, subject to conditions including regulatory, board, shareholder, and Nasdaq approvals. The deal would give Aditxt 9.5% of AiPharma at the initial closing and the remaining 90.5% at the secondary closing, with cash payments and Aditxt share issuance at each step.

Aditxt Enters Revenue-Sharing Agreement with Cellvera in Connection with Proposed Acquisition of Cellvera

April 5, 2022

Biotechnology

Aditxt, Inc. has entered into a revenue-sharing agreement with Cellvera Global Holdings LLC and certain affiliates to support Aditxt’s proposed acquisition of Cellvera. The agreement provides Aditxt with up to 10% of net sales (up to $30 million) while enhancing the security for Cellvera’s loan to Aditxt and extending the due diligence period for the overall transaction.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.

EQT X to Acquire Adalvo (B2B Generic Drug Dossiers)

July 18, 2025

Healthcare Services

EQT X (EQT) has agreed to acquire a majority stake in Adalvo, an asset-light B2B dossier developer that produces market-approval-ready generic drug dossiers for pharmaceutical companies. Existing shareholders, including Aztiq (holding company of Chairman Róbert Wessman), will reinvest part of their holdings and retain minority ownership. The deal is subject to customary approvals and is expected to close in H2 2025.